Meg welcomes Dr. Amy Hauck Newman, the Scientific Director and the Chief of Molecular Targets and Medications Discovery Branch and Medicinal Chemistry Section of the National Institute on Drug Abuse’s Intramural Research Program also known as “NIDA” IRP. It is one of the 27 institutes and centers of the National Institutes of Health (NIH) and it is dedicated to understanding the causes, consequences and treatment of substance use disorders.

On today’s show, Dr. Amy Hauck Newman discusses her work in developing novel medications to treat substance use disorders. She explains the lengthy process of drug development and the importance of intellectual property and partnerships. Dr. Newman also highlights the role of AI and machine learning in healthcare and drug design.

Amy shares her journey into chemistry and the challenges and rewards of starting and leading her own laboratory. The use of drugs like Ozempic is touched on as well as various aspects of substance use disorder and the challenges associated with its treatment. Amy talks about the challenges in treating cocaine and methamphetamine use disorder and the emotional weight of working in this field. Finally, the conversation gets into the challenges in engaging the pharmaceutical industry when it comes to fighting substance use disorders.

Further Reading:

Molecular Targets and Medications Discovery Branch at NIDA

Presynaptic and Postsynaptic Mesolimbic Dopamine D3 Receptors Play Distinct Roles in Cocaine Versus Opioid Reward in Mice

NIH Postbac Program

NIH Summer Internship Program (SIP)

Episode Credits:

The Game-Changing Women of Healthcare is a production of The Krinsky Company.

Hosted by Meg Escobosa.

Produced by Meg Escobosa, Calvin Marty, Chelsea Ho, Medina Sabic, Markala Comfort, and Wendy Nielsen.

Edited, engineered, and mixed by Calvin Marty.

All music composed and performed by Calvin Marty.

©2024 The Krinsky Company